Publications by authors named "Mesfer Alajmi"
This work presents a new framework for a competitive evolutionary game between monoclonal antibodies and signalling pathways in oesophageal cancer. The framework is based on a novel dynamical model that takes into account the dynamic progression of signalling pathways, resistance mechanisms and monoclonal antibody therapies. This game involves a scenario in which signalling pathways and monoclonal antibodies are the players competing against each other, where monoclonal antibodies use Brentuximab and Pembrolizumab dosages as strategies to counter the evolutionary resistance strategy implemented by the signalling pathways.
View Article and Find Full Text PDFArticle Synopsis
- The study introduces a framework for creating personalized treatment plans for esophageal cancer by targeting specific signaling pathways like EGF and VEGF.
- A new pharmacokinetic model is developed to account for differences in these pathways, followed by a three-step process to optimize therapy.
- The process involves solving an optimization problem, performing sensitivity analysis, and then using a modified model to evaluate treatments with Trastuzumab and Bevacizumab, showing effective results.